Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Matthew S. Davids

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Christine E. Ryan

Dana-Farber Cancer Institute

Benjamin L. Lampson

Yue Ren

Svitlana Tyekucheva

Stacey M. Fernandes

Jennifer L. Crombie

1Dana-Farber Cancer Institute, Boston, MA

Austin I. Kim

Matthew Weinstock

Josie Montegaard

Heather A. Walker

Claire Greenman

Victoria Patterson

Caron A. Jacobson

5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Ann S. LaCasce

3Harvard Medical School, Boston, MA

Philippe Armand

4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

David C. Fisher

Steve Lo

Adam J. Olszewski

10Department of Medicine, Brown University, Providence, RI

Jon E. Arnason

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Inhye E. Ahn

1Laboratory of Lymphoid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Jennifer R. Brown